Psilocybin Therapy: From Clinical Trials to Emerging Therapeutic Applications
A broad overview of psilocybin as a therapeutic agent — tracing the arc from Griffiths' 2006 mystical experience study through landmark randomized controlled trials for depression, with a look at the conditions now under active clinical investigation including addiction, OCD, and end-of-life distress.
Content Coming Soon
This resource is being prepared and will be available shortly.
Source Research Papers
Citations in APA 7 format. All studies were sourced from peer-reviewed journals via Google Scholar.
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268–292. https://doi.org/10.1007/s00213-006-0457-5
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994
Shop Related Spores
Laboratory-grade Psilocybe cubensis spore syringes for microscopy research.